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Prevention and Treatment of
Glucocorticoid-Induced Osteoporosis
Mackenzie De Vine, Anh Dao Le, Julie Puvogel, Victoria Cho, Michelle Musser, PharmD, BCPS

This knowledge-based activity is targeted for all pharmacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

ACPE Universal Activity Number (UAN): 0048-0000-16-218-HOl-P
To complete the continuing education program and receive
credit, please go to www.raabecollegeofpharmacy.org/PAW/.

Objectives
After completion of this program, the reader should be able to:
1. Identify the characteristics, pathophysiology and
prevalence of osteoporosis.
2. Recognize patients at risk for or suffering from glucocorticoid-induced osteoporosis.
3. Define the mechanism, efficacy and safety of alendronate, risedronate, zoledronic acid and teriparatide.
4. Identify appropriate treatment plans based on the
FRAX score, risk level and glucocorticoid therapy of
the patient.
5. Recognize the unique advantages of individual therapies and apply them to patient cases.
6. Describe the role of a pharmacist in preventing and
managing glucocorticoid-induced osteoporosis.
Abstract
Osteoporosis is a disease state resulting in decreased bone
mineral density (BMD) and increased risk of fracture, specifi:cally of the vertebrae, spine and hip. Risk factors and high
·risk populations for developing osteoporosis include low
BMD, long-term glucocorticoid therapy, genetics, diet, postmenopausal women and patients with inflammatory or
1chronic disease states. A variety of signaling pathways involving hormones, cytokines and other signaling molecules
are involved in bone formation and are affected by long-term
glucocorticoid therapy, leading to the development of gluco.corticoid-induced osteoporosis (GIO).
There are a variety of drugs that work efficaciously to prevent and treat GIO. Alendronate is a potent bisphosphonate
that has shown efficacy in increasing BMD and decreasing
;bone turnover. Risedronate, another potent bisphosphonate,
:has demonstrated similar effects in patients suffering from
.GIO and has been observed to decrease fractures. Zoledronic
acid is another bisphosphonate option that has proven efficacy and noninferiority to oral bisphosphonates in GIO, but it is
.unique in that it is given intravenously once a year. Additionally, teriparatide is a recombinant human parathyroid hor-
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mone (PTH) which is a newer therapy for the treatment o~
GIO and is beginning to replace older therapies such as tes-1
tosterone and estrogen. The once daily administration of ter-1
iparatide induces bone formation, which allows for increase!
in bone mass thus reducing the risk of vertebral and!
nonvertebral fractures. Furthermore, calcium and vitamin DI
are usually seen as prophylaxis and adjunctive therapy. Atj
the initiation of therapy, pharmacists should recommend
bone density tests to evaluate if medication is appropriate
for the patient. Subsequent action includes patient education
and monitoring of initiated therapy and disease progression.
Key Terms
Alendronate; Bone Density; Bone Remodeling; Chronic Disease; Osteoblasts; Osteogenesis; Osteoporosis; Parathyroid
Hormone; Risedronate Sodium; Risk Factors; Teriparatide;
Vitamin D
Introduction to Osteoporosis
Osteoporosis is characterized by the presentation of low
bone density which may be caused by a variety of factors.!
Clinically, osteoporosis affects the normal daily activities and
quality of life of patients who suffer from this disease. Quality
of life is affected through the increased risk of fracture in
areas such as the hip, vertebrae and wrist. These complications can ultimately lead to significant morbidity and mortality. Common risk factors for osteoporosis include low bone
mineral density (BMD), long-term glucocorticoid therapy and
diet. Populations most affected by osteoporosis include postmenopausal women, patients with inflammatory and chronic
diseases and patients currently taking long-term glucocorticoid therapy.z Symptoms of osteoporosis most commonly
include an increase in fractures (specifically of the vertebrae,
spine and hip) and bone loss detected through BMD testing.
The pathophysiology of osteoporosis is a complex process
involving a variety of cells. It is suggested that bone remodeling plays a large role in the pathophysiology of osteoporosis.3
The processes of bone resorption and deposition, collectively
termed bone remodeling, are dependent upon the activity of
osteoclasts and osteoblasts. Osteoclasts transport protons to
the extracellular space resulting in a lowering of pH and,
therefore, dissolving bone mineral. Osteoblasts deposit bone
mineral. although their mechanism is still not fully understood. These cells communicate to regulate bone remodeling.
Hormones also play a large role in the regulation of
osteoblasts and osteoclasts and are necessary for bone
maintenance and development. In osteoporosis, complex
interactions among cytokines, hormones, pH, osteoblasts and
osteoclasts cause osteoblasts to release signaling molecules
that induce osteoclasts to dissolve bone. This ultimately
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leads to decreased BMD and development and progression of
osteoporosis.
In a global longitudinal study of regional differences in the
treatment of osteoporosis, several gaps in treatment became
evident. In the United States alone, only 52 percent of patients who reported prior fractures of the hip or spine received treatment with an anti-osteoporotic medication.1 Of
patients diagnosed with osteoporosis, only 62 percent receive treatment. Although this seems low, compared to other
countries women in the United States are three times more
likely to be treated for osteoporosis.
Pharmacology of Glucocorticoid-lnduced Osteoporosis
The mechanisms in which glucocorticoids affect the bone to
induce osteoporosis are complex, multifaceted and still not
completely understood (Figure 1). One of the known pathways involved in glucocorticoid-induced osteoporosis (GIO)
is the Wingless-type mouse mammary tumor virus integration site family member (Wnt) signal pathway which has a
role in osteogenesis and the differentiation of osteoblasts. 4.s
Researchers have examined an antagonist of this pathway,
dickkopf-1 (Dkk-1). By testing cultured human osteoblasts,
Ohnaka and colleagues found that when given dexamethasone there was an increased expression of Dkk-1 in the
osteoblastthrough the activation of transcription of the Dkk1 promoter by glucocorticoids. Because the glucocorticoids
upregulate expression of Dkk-1, they ultimately antagonize
the Wnt signaling pathway, interfering with osteoblast signaling for bone formation . A study conducted by Hayashi and
colleagues looked at the expression of certain mRNA proteins
in an osteoblastic precursor cell line when affected by dexamethasone.6 This study showed an increase in a different
Wnt signal inhibitor, axin-2, along with an increased expression in bone morphogenetic protein (BMP) antagonists, follistatin, and Dan. Similar to the Wnt pathway, BMP stimulates
osteogenesis and osteoblast differentiation in bone. Howev-
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er, the expression of follistatin and Dan suppresses proper
osteoblast function. There was also a decrease in Runx2, a
known downstream protein of the BMP pathway, providing
additional evidence that dexamethasone inhibits the pathway.
Glucocorticoids also increase the apoptosis of osteoblasts
and osteocytes while decreasing the production of osteoclasts.7 A study conducted by Weinstein and colleagues
showed mice in the high-dose prednisolone group (2.1 mg/
kg/day) had a significant increase in osteoblast apoptosis in
the vertebral cancellous bone compared to controls (2.03
+/- 0.34 vs. 0.66 +/- 0.07 percent, P < 0.05). Apoptotic osteocytes were also found in cortical bone sections taken from
the femora, in contrast with the absence of apoptotic osteocytes in the control group.
The newest research suggests that glucocorticoids may cause
osteoporosis by a different mechanism by activating the local
renin-angiotensin system in bone.a In a study by Yongtao and
colleagues, rabbits were treated with dexamethasone alone
or with perindopril, an angiotensin-converting enzyme (ACE)
inhibitor. The study found that several genes and proteins
including the sclerostin (SOST) gene, the receptor activator
of nuclear factor-KB ligand (RANKL) to osteoprotegerin
(OPG) ratio, and Runx2 were influenced. The SOST gene is
responsible for the production of sclerostin, which antagonizes the Wnt pathway. The RANKL/OPG ratio increases osteoclastogenesis (higher ratio levels mean more osteoclastic
genes found in mRNA). When treated with dexamethasone
alone, SOST and RANKL/OPG levels were increased, but in
the dexamethasone plus perindopril group, SOST and
RANKL/OPG were significantly lower compared to the dexamethasone alone group. Runx2 was decreased when given
with dexamethasone alone, but it was increased when given
with perindopril. This coincides with the results from the
aforementioned study by Hayashi and colleagues. The effects

Figure 1. Summary of Glucocorticoid Effects on Bone. 4,6,7,B
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(Dkk-1 and sclerostin from SOST gene)
Apoptosis of Osteoclasts
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The increases in Wnt and BMP antagonists interfere with osteoblast signaling ultimately inhibiting osteogenesis.
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of the glucocorticoid were reversed when given an ACE inhibitor. Therefore, the study concluded that the local reninangiotensin system on bone plays a role in GIO, and further
studies are needed to fully understand this mechanism.
Pharmacologic Treatments for Osteoporosis
Bisphosphonates
Bisphosphonates have shown promise as effective therapy in
GIO because of the ability of this drug class to inhibit the resorption of bone while having minimal side effects, thus making therapy more desirable for the patient.9 Bisphosphonates
work to increase BMD by inhibiting bone resorption and the
activity of osteoclasts. Although there are many bisphosphonates, three are particularly recommended by the American
College of Rheumatology for the treatment of GIO: alendronate, risedronate and zoledronic acid.10
Alendronate
Alendronate is a potent second-generation bisphosphonate.9
Alendronate has a high affinity for bone mineral and is taken
up into bone during osteoclast resorption. The drug inhibits
the enzyme farnesyl pyrophosphate synthase which is an
enzyme involved in the mevalonic acid pathway.11 The mevalonic acid pathway affects the production of isoprenoids essential for the modification of small guanosine triphosphate
(GTP) binding proteins. By inhibiting this pathway, alendronate restricts osteoclast survival. It has also demonstrated
effectiveness in increasing BMD of the hip and spine as well

as decreasing the incidence of fractures in these areas, along
with the forearm, in postmenopausal women who suffer
from osteoporosis.12
The American College of Rheumatology's guidelines for alendronate therapy suggests determining the patient's risk category based on their Fracture Risk Assessment Tool (FRAX)
score.10 The FRAX is a questionnaire tool used to assess a
patient's risk of fracture within the next 10 years in patients
who are not being treated and are between the ages of 40
years and 90 years.13 (t can be used with or without
knowledge of the individual patient's BMD in low, medium
and high risk patients. Additionally, there is a strong level of
evidence for the efficacy and use of alendronate in therapy.
Please refer to Table 1 for specific recommendations. At all
risk levels, patient monitoring is recommended. The pharmacist should monitor for additional fractures, modifiable patient risk factors for osteoporosis, patient adherence to therapy and changes in BMn.10 If glucocorticoid therapy is discontinued alendronate may also be discontinued.
Typically, alendronate is dosed once daily, twice weekly or
once weekly. Each regimen has shown near equivalent efficacy in increasing BMD in the hip, neck, trochanter and entire
body.9 It is recommended as a once daily regimen in patients
with GIO receiving systemic steroids. Typically, patients are
given 5 mg by mouth daily. In women who are postmenopausal not taking any type of estrogen replacement therapy,

Table 1. Recommendations for Therapeutic Use in Glucocorticoid-Induced Osteoporosis. 1 0

Glucocorticoid Therapy

Low Risk Patient
(FRAX < 10% fo r
lO year major osteoporosis
fracture)

Medium Risk Patient
(FRAX l0-20% for
10 year major osteoporosis
fracture)

High Risk Patient
(FRAX >20% for
lO year major osteoporosis
fracture)

< 5 mg/day for _::: 1 month

Alendronate
Risedronate
Zoledronic Acid

2: 5 mg/day for_::: 1 month

Alendronate
Risedronate
Zoledronic Acid
Teriparatide

Any dose for 1-3 months

Alendronate
Risedronate
Zoledronic Acid

< 7.5 mg/day for 2: 3 months

2: 7.5 mg/day for 2: 3 months

Alendronate
Risedronate
Zoledronic Acid

Alendronate
Risedronate

Alendronate
Risedronate
Zoledronic Acid
Teriparatide

Alendronate
Risedronate
Zoledronic Acid

Alendronate
Risedronate
Zoledronic Acid
Teriparatide

These recommendations are from the American College of Rheumatology and apply to postmenopausal women and men
over the age of 50 years.
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10 mg by mouth daily is recommended. Patients should remain sitting upright for at least 30 minutes after taking each
dose to avoid esophageal irritation. Bone mineral density
should also be measured at baseline, six months and 12
months. Due to the potential for increased risk of osteonecrosis of the jaw, patients on glucocorticoids should be advised
to have dental exams prior to initiation of bisphosphonates
like alendronate. Patients should also have their renal function and serum calcium levels checked before initiation. If the
creatinine clearance is less than 35 mL/min, alendronate
should not be started. Furthermore, because alendronate
decreases serum calcium levels, hypocalcemia should be corrected before starting therapy, and calcium levels should be
monitored throughout therapy. This medication should be
used with caution in patients suffering from certain gastrointestinal (GI) and esophageal diseases such as esophagitis,
gastritis and gastroesophageal reflux disease due to the increased risk of esophageal irritation associated with this
therapy. The geriatric population is at increased risk for
these reactions and should be monitored for any sign of GI
reactions. Also, this medication is specifically contraindicated
in patients with an increased risk of aspiration or delay of
emptying of the esophagus. Lastly, therapy should be discontinued if the patient develops any signs of dysphasia or retrosternal pain.
In a study conducted by Saag and colleagues, researchers
found that alendronate increased BMD in patients currently
taking glucocorticoid therapy.12 The main goal of the study
was to examine the mean percent change in lumbar-spine
bone density from baseline to week 48 between the groups
receiving different doses of alendronate therapy and placebo.
Secondary outcomes measured bone density changes in the
hip along with new fracture incidence of the vertebrae and
bone turnover markers. The study was a double-blind, randomized, placebo-controlled, multicountry trial. Two different doses of alendronate were studied in men and women
ranging from 17 to 83 years of age without significant differences in baseline characteristics. Patients had been receiving
at least 7.5 mg ofprednisone daily or an equivalent glucocorticoid therapy for underlying chronic diseases. They were
then further divided based on the duration of their glucocorticoid therapy (four months, four to 12 months and more
than 12 months).
The study included 4 77 patients who were randomly assigned to receive 5 mg or 10 mg alendronate or matching
placebo daily.12 The patients were seen at baseline, four, 12,
24, 36 and 48 weeks where researchers reviewed their therapy usage diary. At baseline and every 12 weeks, BMD of the
hip, lumbar area of the spine and whole body were quantified and analyzed. Studies were evaluated using intention-totreat standards. Results were analyzed using the step-down
Tukey trend test which adjusted for multiplicity.
After 48 weeks of therapy, patients receiving 5 mg and 10 mg
of alendronate saw a significant increase (p < 0.001) in the
BMD of the neck, trochanter and lumbar spine. 12 Only 45 percent of the patients in the placebo group saw an increase in
Spring 2016 Volume 7, Issue 2
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the lumbar spine BMD as compared to BO percent in the
treatment group (mostly seen in postmenopausal women).
Whole body BMD significantly increased in the treatment
group on 10 mg of alendronate therapy. Similar side effects
were experienced among groups such as headache, musculoskeletal pain and upper respiratory infection. Patients receiving 10 mg of alendronate reported increased GI adverse
events.
This study concluded that alendronate was efficacious in increasing the BMD in patients with GIO regardless of duration
of glucocorticoid therapy.12 Additionally, bone turnover was
decreased as a result of this therapy.
Risedronate
Risedronate, one of the most potent bisphosphonates, acts by
inhibiting the resorption of bone but does not affect mineralization.14 The action of risedronate is based on its affinity for
the component of bone matrix hydroxyapatite.1s It acts as an
analogue of isoprenoid diphosphate lipids, therefore inhibiting farnesyl pyrophosphate, a key enzyme associated with
the mevalonate pathway. By inhibiting the key enzyme in
osteoclasts that is essential for the synthesis of isoprenoid
lipids, posttranslational modification of small GTPase proteins is inhibited. As a result, osteoclast activity is inhibited,
and bone resorption and turnover are reduced. Also, postmenopausal women have seen a net gain in bone mass with
treatment of risedronate.16
The American College of Rheumatology's guidelines for
risedronate therapy are evaluated in the same manner as
alendronate. 10 Please refer to Table 1 for recommendations
on initiation of treatment of risedronate based on FRAX
score and glucocorticoid therapy. At all risk levels, patient
monitoring is recommended. Additionally, risedronate has a
strong level of evidence in low, medium and high risk patients.
Risedronate is typically dosed once daily, once weekly, once
monthly or twice monthly depending on the condition.14 For
GIO, it is a recommended dosing of 5 mg orally daily before
breakfast in an immediate-release tablet. Patients should
remain sitting upright for at least 30 minutes after receiving
each dose to avoid esophageal irritation. This drug is contraindicated in patients with hypocalcemia or abnormalities of
mineral or bone metabolism such as chronic kidney disease
and certain thyroid disorders. It has been shown to cause
skin reactions such as rash and induce acute bronchospasms
in patients with hypersensitivities to phosphonate or aspirinsensitive asthma. Similar to alendronate, risedronate should
not be used in patients unable to remain sitting upright for
30 minutes after receiving a dose of medication or those who
have esophageal malfunctions. Monitoring should occur for
symptoms of esophageal reactions, dysphasia or retrosternal
pain.
In a multicenter, double-blind, placebo-controlled, parallelgroup study conducted by Reid and colleagues, researchers
aimed to assess the efficacy and safety of risedronate in pa-
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tients taking high dose, long-term glucocorticoid therapy.16
Patient tolerability of this therapy was also assessed. Male
and female patients between the ages of 18 years and 85
years were enrolled from 23 study centers and had been receiving at least 7.5 mg of glucocorticoid therapy for a minimum of six months. A total of 290 patients were enrolled
(109 men and 181 women), and 14 percent of the women
were premenopausal. Patients were divided into three
groups: men, premenopausal women who were either sterile
or using some kind of contraceptive and women who were
postmenopausal for a year or more. Patients were then randomized to receive placebo, 2.5 mg risedronate or 5 mg
risedronate daily for one year. Baseline demographics and
characteristics were comparable among treatment groups.
Patients were required to take the medication with 240 ml of
water 30 to 60 minutes before breakfast on an empty stomach and to remain upright for at least one hour. Additionally,
patients received vitamin D and calcium supplementation.
The study had 90 percent power to detect a difference in
BMD with an alpha level of 0.05 and standard deviation of
5 percent.
The BMD of the lumbar spine, neck, trochanter and forearm
were measured at baseline, six months and 12 months.16 Vertebral fractures were also assessed at baseline and 12
months. Physical examination of the patients was conducted
at six months and 12 months, and laboratory tests were completed at baseline, one month, three months, six months and
12 months. After 12 months of treatment, risedronate
demonstrated significant differences in BMD of the lumbar
spine (p < 0.001), femoral neck (p < 0.004) and trochanter
(p < 0.001). Patients receiving the 5 mg dose of risedronate
saw an increase in BMD by 2.9 percent in the lumbar spine,
1.8 percent in the femoral neck and 2.4 percent in the trochanter. In patients receiving 2.5 mg of risedronate, there
was a small increase in spinal BMD which was not significant
when compared to the placebo group. In the radius, BMD
was maintained in patients receiving 5 mg risedronate, while
there was a loss of BMD in the placebo group. A further subgroup analysis of patients receiving 5 mg risedronate
demonstrated that 5 mg therapy, relative to placebo, increased the BMD at all sites in both men and postmenopausal women. Due to the small population of premenopausal
women in the study, their results were not considered significant. Risedronate 5 mg therapy was also shown to increase
BMD in patients with underlying chronic disease
(rheumatoid arthritis, lung disease). Although these results
were not statistically significant, there was a positive correlation.
Nearly 15 percent of patients in the placebo group experienced fractures, while only 5 percent of the patients in the
treatment group experienced fractures, at 12 months.16 A
reduction of 70 percent in fractures of the vertebrae, as compared to placebo, was calculated for both risedronate groups.
Significance was found overall in the lumbar spine, femoral
neck and femoral trochanter in both the 2.5 mg and 5 mg
treatment groups (p < 0.001, p < 0.004, p < 0.010, respectively). Also, reported adverse events were similar among treat-
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ment and placebo groups. The treatment groups receiving
5 mg risedronate reported a higher incidence of back pain
and arthralgia when compared to placebo. However, these
side effects, along with other GI symptoms such as abdominal pain and gastritis, were mild and not considered
relevant. Gastrointestinal side effects were reported but
were similar among treatment and placebo groups; none
being reported as severe.
Overall, Reid and colleagues showed that in patients on high
doses of long-term glucocorticoid therapy, 5 mg of
risedronate significantly increases BMD while dosing of
2.5 mg is less effective.16 Additionally, fractures were reduced in the treatment groups as compared to the placebo
group. There was a significant increase (3 percent) in BMD of
the lumbar spine after 12 months of therapy with 5 mg
risedronate, in addition to a significant increase in BMD of
the trochanter and femoral neck. Risedronate was also well
tolerated in the study and can be recommended in the studied patient population.
Zoledronic Acid (Reclast®) Parenteral Therapy
Zoledronic acid is a bisphosphonate that is unique in its administration and frequency. It targets farnesyl pyrophosphate synthase in osteoclasts located in areas of high bone
turnover.17 The drug only needs to be administered intravenously once a year because of its high affinity for mineralized
bone. This schedule is appealing for prescribers with patients that have compliance issues.
The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) group performed a year long,
randomized, double-blind, double-dummy, noninferiority
study comparing zoledronic acid with risedronate.1s Both
genders aged 18 to 85 years could participate in the study.
The main goal of the study was to prove that zoledronic acid
5 mg intravenously is noninferior to oral risedronate 5 mg
daily when looking at percentage change from baseline in
BMD of the lumbar spine (primary outcome), total hip, femoral neck, trochanter and distal radius (secondary outcomes)
after 12 months. Bone turnover markers and adverse events
were also compared and assessed. All patients in the study
were required to take vitamin D and calcium before the trial
began and throughout the trial. The groups were randomized
in a one to one ratio into either the zoledronic acid group or
the risedronate group and also into either a treatment or
prevention group based on the initiation of glucocorticoid
therapy (less than three months was considered prevention
and greater than three months was considered treatment).
The trial confirmed that zoledronic acid is noninferior to
risedronate in the treatment and prevention of GIO. The
HORIZON group concluded that after 12 months zoledronic
acid increased lumbar spine BMD in prevention and treatment when assessed at all test areas of the body with the
exception of the prevention of GIO of the distal radius. Perhaps more importantly, when the BMD of the lumbar spine
was tested at six months it was significantly higher than the
risedronate group. This is significant because patients can
start to see GIO within a few months of glucocorticoid thera-
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py. Therefore, the faster a drug can begin showing considerable effects ofGIO prevention or treatment, the better.
In the HORIZON study, zoledronic acid did have significantly
higher occurrence of adverse events as compared to
risedronate.1s The study found within the first three days
after the infusion of zoledronic acid, flu-like illnesses and
pyrexia were reported; however, after that time period
elapsed, reporting of adverse events was similar between the
groups. A review article discussing the management of common adverse events associated with intravenous bisphosphonates found flu-like illnesses to be frequently reported
but transient in duration.19 The most severe adverse event
reported for both groups was worsening of rheumatoid arthritis, and the main difference was seen in the higher reporting of pyrexia in the patients receiving zoledronic acid.18
The administration of acetaminophen immediately following
the infusion of zoledronic acid is suggested to reduce frequency or duration of pyrexia, myalgia, arthralgia and headache within the first three days.17
The HORIZON study convinced the American College of
Rheumatology to include zoledronic acid in their 2010 recommendations for the prevention and treatment of GI0.10
The recommendations according to FRAX score can be found
in Table 1. Because the FRAX score can only be used in postmenopausal patients or men over 50 years of age, there are
also recommendations for premenopausal women and men
less than 50 years of age that have a history of fragility fracture. Zoledronic acid is recommended if taking at least
7.5 mg of prednisone for one to three months and of
nonchildbearing potential. If at least three months of glucocorticoid therapy are expected for those with a history of
fragility fractures and of nonchildbearing potential,
zoledronic acid is a recommendation for any dose. Zoledronic acid is not recommended for women of childbearing potential. All of the recommendations provided were level B
evidence, meaning that the data came from a single, randomized, controlled trial or nonrandomized study.
The absolute contraindications for zoledronic acid therapy
include hypocalcemia (unless adequately treated), a creatinine clearance less than 35 mL/min or evidence of acute
renal impairment, pregnancy, and hypersensitivity to any
component in zoledronic acid.17 Patient warnings include osteonecrosis of the jaw, atypical femoral fractures, musculoskeletal pain and bronchoconstriction in aspirin-sensitive patients.
While these are very rare side effects, patients should receive
appropriate education about these possible occurrences and
what to do if they occur. Zoledronic acid should be considered
in patients that have compliance problems and could be considered a first-line option for many patients as evidenced by a
survey at the end of the HORIZON study.is The survey asked
patients to comment on their preferences of route of administration regarding convenience, satisfaction and willingness
to use long term. Most patients reported in the survey that
they favored the intravenous preparation over the oral for
convenience and satisfaction and stated they were willing to
take the intravenous preparation.
Spring 2016 Volume 7, Issue 2
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Teriparatide
Glucocorticoid therapy induces bone loss by inhibiting osteoblast formation and activating osteoblast apoptosis.20 Teriparatide is a recombinant human parathyroid hormone
(PTH), which is a newer therapy for the treatment of GIO,
and replaces older therapies such as testosterone and estrogen.10 The administration of teriparatide once daily induces
bone formation, which allows for an increase in bone mass
thus reducing the risk of vertebral and nonvertebral fractures.20
Please refer to Table 1 for the American College of Rheumatology's guidelines for recommendations of the therapeutic
usage of teriparatide based on FRAX score and glucocorticoid
therapy. 10 Similar to the previously mentioned medications,
patient monitoring is recommended during usage. In addition to the recommendations above, for premenopausal
women who have childbearing potential along with a fragility fracture, teriparatide is recommended if the patient is on
glucocorticoids (dose of 7.5 mg or more of prednisone) for
more than three months. For men below 50 years of age, teriparatide is recommended if glucocorticoid usage is longer
than three months and if a fragility fracture exists. Currently,
the use of teriparatide therapy for GIO is only approved for at
most 24 months of therapy.21
The effectiveness of the teriparatide was studied in a randomized, double-blind, controlled trial conducted by Saag
and colleagues.20 Teriparatide was compared with alendronate in 428 females and males who were diagnosed with
established glucocorticoid-induced osteoporosis. These patients were defined as patients diagnosed with osteoporosis
and were on a glucocorticoid therapy for at least three
months.
Two hundred fourteen patients were randomly assigned to
either receive 20 mcg of subcutaneous injectable teriparatide
once daily with an oral placebo or 10 mg of alendronate once
daily orally with an injectable placebo. Patients also received
1000 mg calcium carbonate and vitamin D daily. There were
no significant differences between the patients in the two
study groups when baseline characteristics were accounted.
The study was conducted for 18 months. The main focus of
the study was to measure the change in BMD of the lumbar
spine from baseline to 18 months. Additional outcomes assessed included changes in BMD at the total hip, markers of
bone turnover, and the time to fluctuations in BMD, occurrence of fractures, and safety.
It was found that the mean BMD in the lumbar spine improved more in the teriparatide group than in the alendronate group (teriparatide: 7.2 ± 0.7 percent and alendronate:
3.4 ± 0.7 percent, P < 0.001). There was a significant difference (P < 0.001) between the groups six months into the
study. At 18 months, the measured difference from baseline
for teriparatide was 3.8 ± 0.6 percent but only 2.4 ± 0.6 percent for alendronate. When analyzing markers of bone turnover, N-terminal propeptide of type I collagen served as an
indicator of bone formation. C-telopeptide of type I collagen
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served as an indicator of resorption. Both of these markers
increased 69.8 percent and 44.8 percent measuring from
baseline, respectively. Alendronate showed a decrease in
markers followed by constant suppressed levels. The teriparatide group also had fewer new vertebral fractures than in
the alendronate group showing a 0.6 percent occurrence in
the teriparatide group and 6.1 percent occurrence in the
alendronate group while P = 0.004. It was shown that there
were more nonvertebral fractures for patients who received
teriparatide. However, the occurrence of nonvertebral frac"
tures did not show a big difference with 5.6 percent occurrence in the teriparatide group versus 3. 7 percent in the
alendronate group with P=0.36.
Osteoporosis patients have a lowered ability to convert
25-hydroxyvitamin D [25(0H)D] to 1,25 dihydroxyvitamin D
[1,25(0H)2D], which is the active form.22 Cosman and colleagues found that with doses greater than 7.5 mg per day,
teriparatide increased renal activity in order to promote the
conversion of vitamin D. The increased vitamin D conversion
to its active form allows for an increased calcium absorption
in the GI tract, renal conservation of calcium, skeletal calcium
release and increase in serum calcium concentrations. This is
supported by the study conducted by Saag and colleagues
which showed that, similar to the 18 month study, the 36
month study showed teriparatide patients with elevated serum calcium levels 21 percent compared to only 7 percent in
alendronate patients.23
Adverse events of teriparatide use reported include nausea,
insomnia, pharyngitis, viral infection, headache, dizziness
and injection site reactions.zo Three patients experienced
hyperuricemia and one patient experienced gout in the teriparatide group, but these adverse events did not occur in the
alendronate group.
Patients with osteoporosis and elevated risk for fracture
showed more improvement in BMD while receiving
teriparatide when compared to patients who received
alendronate.zo Since BMD increased more with the usage of
teriparatide therapy in GIO, it is associated with a higher volumetric BMD than alendronate.
Although teriparatide use should not exceed 24 months, a 36
month follow-up study by Saag and colleagues was conducted and found that patients treated with teriparatide showed
greater increases in BMD of the lumbar spine (11 percent
versus 5.3 percent) and fewer new vertebral fractures than
subjects treated with alendronate.23
Calcium and Vitamin D
Clinicians have often struggled to find the correct place for
calcium and vitamin D in the treatment of osteoporosis. A
double-blind, parallel-group study, performed by Sambrook
and colleagues, randomized patients on corticosteroids into
three groups: group 1 took calcitriol, salmon calcitonin nasal
spray, and elemental calcium; group 2 took the same but had
a placebo nasal spray; group 3 took calcium and placebos of
the calcitriol and calcitonin.24 The study looked at the effects
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of the therapies on BMD while on corticosteroids. They found
that calcium plus calcitriol, with or without calcitonin, prevented bone loss from the lumbar spine. The study also
looked at the femoral neck and the distal radius, but none of
the treatment groups prevented bone loss in these locations.
Sambrook and colleagues also did a later study that was randomized and open labeJ.25 This study compared calcitriol,
vitamin D (ergocalciferol) plus calcium and alendronate plus
calcium. Bone mineral density of the lumbar spine was measured every six months from baseline for two years, and femoral neck and total body were also measured as secondary
end points of the study. Results from the study indicated that
alendronate plus calcium was superior to the other treatments in the study. This was especially noticeable in the initial bone loss phase.
Because drugs that work more efficaciously in the prevention
and treatment of GIO are now considered first-line, calcium
and vitamin D are usually seen as adjunctive therapy.10 In
studies that deal with the treatment of GIO, most often the
patients in the treatment groups are also receiving some type
of calcium and vitamin D supplementation.12,1s
Prevention of GIO
All patients on glucocorticoids should engage in weightbearing exercise like running or lifting to stimulate bone
remodeling. 10 Regardless of the strength or duration of
glucocorticoid therapy, patients should receive 1200 to
1500 mg/day of calcium (diet or supplement) in addition to
800 to 1000 JU/day of vitamin D. All of the aforementioned
drugs can be initiated with the start of glucocorticoid therapy
as either prevention or treatment. See Table 2 for dosage
recommendations.
The Pharmacist's Role
It is estimated that more than 1 million people in the United
States alone are on long-term glucocorticoid therapy.26 This
type of therapy elevates patients to a higher risk of osteoporosis and fractures. Most of the adverse events of the glucocorticoids occur during the first six months of therapy.
Patients on long-term glucocorticoid therapy require education and monitoring.26 Pharmacists are readily available to
help counsel these patients as they have the most knowledge
about medications. These two factors make pharmacists, especially community pharmacists, prime candidates to assist
patients who have or are at risk for GIO. Through counseling
and education, pharmacists can increase patient awareness
of potential risks of long-term use of glucocorticoids.27 They
can inform patients that cigarette smoking, excessive alcohol
intake, an inactive lifestyle and hypogonadism can increase
their risk for developing GIO.
McDonough and colleagues conducted a randomized control
design where 15 community pharmacies were randomized
to either the control group (which provided usual patient
care) or the treatment group (which provided patients with
education about the risks of GI0).27 The treatment group re-
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Table 2: Dosing for Prevention of Glucocorticoid-Induced Osteoporosis.9,10.14,11

Route

Dose

Frequency

Alendronate

Oral

5 mg/ 35 mg

Daily/Weekly

Risedronate

Oral

5 mg/ 35 mg

Daily /Weekly

Intravenous

Smg

Annually

Subcutaneous

20mcg

Daily

Drug

Zoledronic Acid

Teri para tide

ceived education via pamphlets. The pharmacists monitored
patient drug therapies and looked for potential drug-related
issues. Osteoporosis risk factors were then collected through
patient surveys after nine months. Variables such as using
calcium supplements, discussion of GIO risk, discussion of
bone density tests, reported inactivity and reported low calcium diets were compared between the two groups. There
was only a significant difference between the two groups
when the frequency of patients taking a calcium supplement
was analyzed: control group (-6.9 percent) and the treatment
group (17.1 percent) with P < 0.05. This study shows that
community pharmacists are able to increase vitamin supplementation for patients on glucocorticoid therapy.
Additionally, pharmacists can help identify high-risk patients
before glucocorticoid therapy starts and, as a result, educate
patients about their risk for GIO, recommend a BMD test and
potentially collaborate with a physician to initiate therapy to
prevent GIO occurrence.26, 20 It is recommended that patients
start therapy on the lowest dose of glucocorticoids for the
shortest length of therapy to minimize GIO risk. Patients beginning glucocorticoid therapy that will last longer than
three months should be advised to have the following tests:
fall risk assessment, baseline dual x-ray absorptiometry, serum 25-hydroxyvitamin D level, baseline height, assessment
of prevalent fragility fractures and radiographic imaging of
spine or vertebra.10 Patients should also consider appropriate lifestyle changes such as weight-bearing activities and
exercise, fall prevention, smoking cessation and avoidance of
excessive alcohol consumption (> two drinks/day). Furthermore, pharmacists should counsel patients on medication
usage, calcium and vitamin D supplementation and the importance of adherence.10,2s
For patients who have been taking glucocorticoids for longer
than three months, pharmacists should advise patients to
consult their doctors about periodically receiving serial bone
mineral density testing, assessments for incident fragility
fracture, osteoporosis medication compliance, annual serum
25-hydroxyvitamin D measurements and height measurements to monitor for Gro.10
Spring 2016 Volume 7, Issue 2

When reviewing patient profiles, pharmacists should be alert
for red flags in regard to glucocorticoid therapy and GI0.27
They should watch for medications that may interact with
glucocorticoids such as thyroid hormone supplements and
anticonvulsants. Additionally, pharmacists should check profiles or ask patients on glucocorticoids if they are also taking
recommended calcium and vitamin D supplementation.
Also, pharmacists can determine when a drug holiday is necessary by analyzing therapy duration of past therapy and
patient risk factors. A drug holiday is a break in therapy
designed to reduce the risks of long-term glucocorticoid
treatment.26 Patients on drug holiday should be monitored;
presenting an ideal role for the pharmacist. If the BMD decreases significantly, or if occurrence of fractures takes place,
therapy should resume. If a patient is on an osteoporosis
treatment holiday, the pharmacist can create an action plan
and follow up with the patient every one to two years. Pharmacists can also reassess a patient's risk of fracture by utilizing FRAX to help identify when it would be appropriate to
start or end a drug holiday.
Pharmacists can prevent and treat GIO via monitoring, educating patients on lifestyle and diet alterations, and providing
therapeutic management. 26 Community pharmacists readily
interact with physicians, allowing for initiation of a management process to reduce GIO. Utilizing these methods will allow for better therapeutic outcomes with interprofessional
work between the pharmacist and physician along with communication with patient.
Conclusion
Osteoporosis is characterized by the presentation of low
bone density influenced by individualized factors. The disease has also been shown to occur in the vast majority of patients on long-term glucocorticoid therapy. The development
of GIO poses negative effects on the patient by hindering
their ability to complete daily activities and lowering their
quality of life through the increased risk of fracture in areas
such as the hip, vertebrae and wrist. Prevention of GIO by
utilizing nonpharmacologic measures such as weight-bearing
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exercises like running or lifting to stimulate bone remodeling
is recommended with any glucocorticoid therapy.
The same medications used for prevention are also used for
treatment of GIO. Medication therapy options most frequently recommended to treat GIO consist of bisphosphonates,
including alendronate oral therapy, risedronate oral therapy
or zoledronic acid parenteral therapy. The most recent addition to the guidelines is teriparatide, a subcutaneous injectable therapy. Recommendations are made based on the
patient's FRAX score and glucocorticoid treatment plan and
are individualized to best fit the patient's lifestyle. The concurrent use of supplements such as calcium and vitamin D is
beneficial to help build up BMD. Both supplements have been
found to significantly improve BMD and lower fracture risk
in patients.
Although therapeutic outcomes depend on patient compliance, the pharmacist can play an important role in glucocorticoid therapy. Pharmacists should counsel and assess the
appropriateness of each medication to prevent GIO. After
therapy is initiated, pharmacists should be involved in monitoring the wellness of the patient and evaluating if additional
therapy is necessary.
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Assessment Questions
1.

2.

3.

JD, a 65 year old female, is receiving prednisone 15 mg
daily as maintenance therapy for autoimmune hepatitis.
JD's FRAX score indicates she is at high risk for
(glucocorticoid-induced) osteoporosis. Which of the following would be appropriate therapy for JD?
A. Alendronate therapy.
B. Discontinuation of maintenance prednisone.
C. Calcium and vitamin D supplementation only.
D. No pharmacologic intervention is necessary at
this time.
Patients taking glucocorticoid therapy for at least __
have a significant increase in developing osteoporosis.
A. 1-2 months
B. 4-8 months
C. 3-6 months
D. 1 year
The pathophysiology of osteoporosis involves:
A. Hormones
B. Osteoclasts
C. Osteoblasts
D. All of the above

8.

What does teriparatide stimulate?
A. Osteoblast apoptosis
B. Osteoclasts
C. Osteoblastogenesis
D. Glucocorticoid-induced Osteoporosis

9.

What is the usual dose of teriparatide for GIO patients?
A. Oral: 20 mg once daily
B. Sublingual: 200 mcg once daily
C. SubQ: 20 mcg once daily
D. IM: 20 mcg once daily

10. Pharmacists should counsel on _ _ _ and _ _ __

4.

What dose of risedronate has been shown to significantly
increase bone mineral density in patients with GIO?
A. 2 mg
B. 5mg
C. 7.5 mg
D. 12.5 mg

5.

JL's doctor has identified him as a high-risk patient that
needs to be started on therapy to prevent glucocorticoidinduced osteoporosis. His doctor knows that JL frequently misses appointments and never calls regarding refills
for his hypertension medication. Which medication
would you suggest for JL?
A. Alendronate
B. Zoledronic Acid
C. Risedronate
D. Calcium alone will show benefit.

6.

7. Which of the following is a contraindication to zoledronic acid therapy?
A. Untreated hypocalcemia
8. CrCl < 35 mL/min
C. Pregnancy
D. All of the above are contraindications to
zoledronic acid therapy.

supplementation when a patient starts a glucocorticoid
therapy for a duration longer than three months.
A. fish oil; St. John's Wort
B. vitamin C; calcium
C. vitamin A; vitamin C
D. vitamin D; vitamin A

Ohio Northern University is accredited by the
Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education. This
program is eligible for credit until 12/2/2019.

To complete the continuing education program and receive
credit, please go to www.raabecollegeofpharmacy.org/PAW/
to enter the required information. Please allow two to three
weeks for electronic distribution of your continuing education certificate, which will be sent to your valid email address
in PDF format.

The 2010 American College ofRheumatology guidelines
recommend
of calcium and
of vitamin D.
A. 1200-1500 mg/day; 800-1000 IU/day
B. 800-1000 IU/day; 1200-1500 mg/day
C. 2200-2500 mg/day; 80-100 JU/day
D. 80-100 JU/day; 2200-2500 mg/day

Spring 2016 Volume 7, Issue 2

THE PHARMACY AND WELLNESS REVIEW

21

